

January 23, 2026

The Honorable Mike Johnson
Speaker of the House
U.S. House of Representatives
Washington, DC 20515

The Honorable John Thune
Majority Leader
U.S. Senate
Washington, DC 20510

The Honorable Hakeem Jeffries
Minority Leader
U.S. House of Representatives
Washington, DC 20515

The Honorable Charles Schumer
Minority Leader
U.S. Senate
Washington, DC 20510

The Honorable Susan Collins
Chair, Senate Appropriations Committee
U.S. Senate
Washington, DC 20510

The Honorable Tom Cole
Chair, House Appropriations Committee
U.S. House of Representatives
Washington, DC 20515

The Honorable Patty Murray
Vice Chair, Senate Appropriations Committee
U.S. Senate
Washington, DC 20510

The Honorable Rosa DeLauro
Ranking Member, House Appropriations Committee
U.S. House of Representatives
Washington, DC 20515

Dear Majority Leader Thune, Minority Leader Schumer, Speaker Johnson, Minority Leader Jeffries, Chair Collins, Vice Chair Murray, Chair Cole and Ranking Member DeLauro:

The Infectious Diseases Society of America (IDSA) and the HIV Medicine Association (HIVMA) and our more than 13,000 infectious diseases physicians and scientists support the bipartisan FY 2026 Labor, Health and Human Services, Education and Related Agencies funding agreement. We are grateful to the House for passing the legislation on January 22, and we urge the Senate to do so by Jan. 30. Our organizations appreciate funding in the bill for infectious diseases and HIV programs at the Centers for Disease Control and Prevention, the National Institutes of Health, the Health Resources and Services Administration, and the Administration for Strategic Preparedness and Response/Biomedical Advanced Research and Development Authority. Our members are particularly grateful for provisions in the bill that strengthen congressional oversight to help ensure that the Administration utilizes funding as Congress intends, extend telehealth flexibilities, and provide important protections for the federal health workforce, NIH indirect rates and the NIH organizational structure.

IDSA and HIVMA are pleased that the bill sustains funding for lifesaving ID and HIV programs. Looking ahead, we strongly encourage you to make deeper investments in FY 2027 to better support the ID workforce and combat antimicrobial resistance. We also emphasize that an immediate extension of the enhanced marketplace premium tax credits enacted in 2021 is urgently needed to prevent millions of Americans from losing their health care coverage. People with HIV have already begun losing their 2026 health care coverage and access to HIV treatment as a result of the premium increases, putting their lives at risk.



Our members and their patients are grateful for your leadership to protect Americans from infectious diseases. If we can serve as a resource for your efforts, please have your staff contact Lisa Cox, IDSA director of government relations, at lcx@idsociety.org, or Jose Rodriguez, HIVMA associate director, public policy and advocacy, at jrodriguez@hivma.org.

Sincerely,

Ronald G. Nahass, MD, MHCM, FIDSA
President, IDSA

Anna K. Person, MD, FIDSA
Chair, HIVMA